Baldwin Brothers Inc. MA Takes $268,000 Position in Sanofi (SNY)
Baldwin Brothers Inc. MA bought a new position in Sanofi (NYSE:SNY) in the third quarter, according to the company in its most recent filing with the SEC. The fund bought 5,379 shares of the company’s stock, valued at approximately $268,000.
Other institutional investors also recently made changes to their positions in the company. Parallel Advisors LLC boosted its holdings in shares of Sanofi by 42.5% in the 2nd quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock worth $139,000 after purchasing an additional 875 shares during the period. YorkBridge Wealth Partners LLC boosted its holdings in shares of Sanofi by 33.7% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 3,076 shares of the company’s stock worth $147,000 after purchasing an additional 776 shares during the period. Eagle Ridge Investment Management purchased a new position in shares of Sanofi in the 2nd quarter worth approximately $160,000. Bronfman E.L. Rothschild L.P. boosted its holdings in shares of Sanofi by 142.8% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,567 shares of the company’s stock worth $171,000 after purchasing an additional 2,098 shares during the period. Finally, Toronto Dominion Bank boosted its holdings in shares of Sanofi by 4.6% in the 2nd quarter. Toronto Dominion Bank now owns 4,054 shares of the company’s stock worth $195,000 after purchasing an additional 180 shares during the period. Hedge funds and other institutional investors own 9.35% of the company’s stock.
SNY has been the subject of a number of recent research reports. BidaskClub cut Sanofi from a “buy” rating to a “hold” rating in a report on Wednesday, July 5th. Cowen and Company reiterated a “market perform” rating and issued a $52.00 target price (up previously from $46.00) on shares of Sanofi in a report on Tuesday, August 1st. HSBC Holdings plc upgraded Sanofi from a “reduce” rating to a “hold” rating in a report on Wednesday, August 30th. Argus reiterated a “buy” rating and issued a $55.00 target price on shares of Sanofi in a report on Friday, September 1st. Finally, J P Morgan Chase & Co reiterated a “neutral” rating on shares of Sanofi in a report on Friday, September 15th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $53.50.
In other Sanofi news, major shareholder Sanofi acquired 105,820 shares of the stock in a transaction that occurred on Thursday, August 24th. The stock was bought at an average cost of $482.04 per share, for a total transaction of $51,009,472.80. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.00% of the company’s stock.
Sanofi (SNY) traded down 0.0978% during trading on Tuesday, reaching $47.3836. The company had a trading volume of 118,650 shares. The firm has a market capitalization of $119.00 billion, a price-to-earnings ratio of 11.3602 and a beta of 0.87. The company’s 50-day moving average is $49.34 and its 200 day moving average is $48.48. Sanofi has a 52 week low of $38.40 and a 52 week high of $50.65.
Sanofi (NYSE:SNY) last posted its quarterly earnings results on Monday, July 31st. The company reported $0.74 EPS for the quarter, meeting the consensus estimate of $0.74. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The firm had revenue of $8.66 billion during the quarter, compared to analysts’ expectations of $8.71 billion. The business’s quarterly revenue was down 2.3% on a year-over-year basis. Equities analysts anticipate that Sanofi will post $3.32 EPS for the current year.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with Analyst Ratings Network's FREE daily email newsletter.